Cellular immune controls over Epstein-Barr virus infection: New lessons from the clinic and the laboratory

Trends in Immunology

Volumn 35, Issue 4, 2014, Pages 159-169

  Rickinson, Alan B ^a   Long, Heather M ^a   Palendira, Umaimainthan ^b   Münz, Christian ^c   Hislop, Andrew D ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Animal models; Epstein Barr virus; Immunodeficiency; NK cells; T cells

Indexed keywords

CELLULAR IMMUNITY; EPSTEIN BARR VIRUS INFECTION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE DEFICIENCY; MONONUCLEOSIS; NONHUMAN; REVIEW; RHESUS MONKEY; STEM CELL; VIRUS VIRULENCE; X CHROMOSOME LINKED DISORDER; ANIMAL; DISEASE MODEL; IMMUNOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; IMMUNITY, CELLULAR;

EID: 84897438282     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2014.01.003     Document Type: Review

References (103)

1. Balfour H.H., et al. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J. Infect. Dis. 2013, 207:80-88.
2. Williams H., et al. The immune response to primary EBV infection: a role for natural killer cells. Br. J. Haematol. 2005, 129:266-274.
3. Moormann A.M., et al. Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. J. Infect. Dis. 2005, 191:1233-1238.
4. Silins S.L., et al. Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. Blood 2001, 98:3739-3744.
5. Clute S.C., et al. Cross-reactive influenza virus-specific CD8+ T cells contribute to lymphoproliferation in Epstein-Barr virus-associated infectious mononucleosis. J. Clin. Invest. 2005, 115:3602-3612.
6. Odumade O.A., et al. Primary Epstein-Barr virus infection does not erode preexisting CD8(+) T cell memory in humans. J. Exp. Med. 2012, 209:471-478.
7. Sundstrom Y., et al. The expression of human natural killer cell receptors in early life. Scand. J. Immunol. 2007, 66:335-344.
8. Pappworth I.Y., et al. The switch from latent to productive infection in epstein-barr virus-infected B cells is associated with sensitization to NK cell killing. J. Virol. 2007, 81:474-482.
9. Griffin B.D., et al. EBV BILF1 evolved to downregulate cell surface display of a wide range of HLA class I molecules through their cytoplasmic tail. J. Immunol. 2013, 190:1672-1684.
10. Stewart C.A., et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:13224-13229.
11. Ferlazzo G., et al. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:16606-16611.
12. Strowig T., et al. Tonsilar NK cells restrict B cell transformation by the Epstein-Barr virus via IFN-gamma. PLoS Pathog. 2008, 4:e27.
13. Lunemann A., et al. A distinct subpopulation of human NK cells restricts B cell transformation by EBV. J. Immunol. 2013, 191:4989-4995.
14. Chung B.K., et al. Innate immune control of EBV-infected B cells by invariant natural killer T cells. Blood 2013, 122:2600-2608.
15. Allan L.L., et al. CD1d and CD1c expression in human B cells is regulated by activation and retinoic acid receptor signaling. J. Immunol. 2011, 186:5261-5272.
16. Odumade O.A., et al. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin. Microbiol. Rev. 2011, 24:193-209.
17. Hislop A.D., et al. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu. Rev. Immunol. 2007, 25:587-617.
18. Blake N., et al. The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1. J. Immunol. 2000, 165:7078-7087.
19. Mackay L.K., et al. T cell detection of a B-cell tropic virus infection: newly-synthesised versus mature viral proteins as antigen sources for CD4 and CD8 epitope display. PLoS Pathog. 2009, 5:e1000699.
20. Tellam J., et al. Regulation of protein translation through mRNA structure influences MHC class I loading and T cell recognition. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:9319-9324.
21. Tellam J.T., et al. Messenger RNA sequence rather than protein sequence determines the level of self-synthesis and antigen presentation of the EBV-encoded antigen, EBNA1. PLoS Pathog. 2012, 8:e1003112.
22. Apcher S., et al. mRNA translation regulation by the Gly-Ala repeat of Epstein-Barr virus nuclear antigen 1. J. Virol. 2009, 83:1289-1298.
23. Apcher S., et al. Epstein Barr virus-encoded EBNA1 interference with MHC class I antigen presentation reveals a close correlation between mRNA translation initiation and antigen presentation. PLoS Pathog. 2010, 6:e1001151.
24. Pudney V.A., et al. CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J. Exp. Med. 2005, 201:349-360.
25. Abbott R.J., et al. CD8+ T cell responses to lytic EBV infection: late antigen specificities as subdominant components of the total response. J. Immunol. 2013, 191:5398-5409.
26. Ressing M.E., et al. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products. Semin. Cancer Biol. 2008, 18:397-408.
27. Rowe M., Zuo J. Immune responses to Epstein-Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunity. Microbes Infect. 2010, 12:173-181.
28. Adhikary D., et al. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J. Exp. Med. 2006, 203:995-1006.
29. Long H.M., et al. Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition. J. Immunol. 2011, 187:92-101.
30. Long H.M., et al. MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response. J. Exp. Med. 2013, 210:933-949.
31. Henle W., et al. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:570-574.
32. Hille A., et al. Expression of Epstein-Barr virus nuclear antigen 1,2A and 2B in the baculovirus expression system: serological evaluation of human antibodies to these proteins. J. Med. Virol. 1993, 39:233-241.
33. Balfour H.H., et al. A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis. J. Infect. Dis. 2005, 192:1505-1512.
34. Taylor G.S., et al. A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells. J. Immunol. 2006, 177:3746-3756.
35. Leung C.S., et al. Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:2165-2170.
36. Gannage M., et al. Antigen processing for MHC presentation via macroautophagy. Methods Mol. Biol. 2013, 960:473-488.
37. Fafi-Kremer S., et al. Long-term shedding of infectious epstein-barr virus after infectious mononucleosis. J. Infect. Dis. 2005, 191:985-989.
38. Parvaneh N., et al. Primary immunodeficiencies predisposed to Epstein-Barr virus-driven haematological diseases. Br. J. Haematol. 2013, 162:573-586.
39. Orange J.S. Natural killer cell deficiency. J. Allergy Clin. Immunol. 2013, 132:515-525. quiz 526.
40. de Vries E., et al. Identification of an unusual Fc gamma receptor IIIa (CD16) on natural killer cells in a patient with recurrent infections. Blood 1996, 88:3022-3027.
41. Jawahar S., et al. Natural Killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). Clin. Exp. Immunol. 1996, 103:408-413.
42. Grier J.T., et al. Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity. J. Clin. Invest. 2012, 122:3769-3780.
43. Eidenschenk C., et al. A novel primary immunodeficiency with specific natural-killer cell deficiency maps to the centromeric region of chromosome 8. Am. J. Hum. Genet. 2006, 78:721-727.
44. Gineau L., et al. Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency. J. Clin. Invest. 2012, 122:821-832.
45. Hughes C.R., et al. MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans. J. Clin. Invest. 2012, 122:814-820.
46. Biron C.A., et al. Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med. 1989, 320:1731-1735.
47. Mace E.M., et al. Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset. Blood 2013, 121:2669-2677.
48. Spinner M.A., et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics and immunity. Blood 2014, 10.1182/blood-2013-07-515528.
49. McClain K.L., et al. Association of Epstein-Barr virus with leiomyosarcomas in children with AIDS. N. Engl. J. Med. 1995, 332:12-18.
50. Purgina B., et al. AIDS-related EBV-associated smooth muscle tumors: a review of 64 published cases. Patholog. Res. Int. 2011, 10.4061/2011/561548.
51. Shaw R.K., et al. Bilateral adrenal EBV-associated smooth muscle tumors in a child with a natural killer cell deficiency. Blood 2012, 119:4009-4012.
52. Greenspan J.S., et al. Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. N. Engl. J. Med. 1985, 313:1564-1571.
53. Huck K., et al. Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J. Clin. Invest. 2009, 119:1350-1358.
54. Stepensky P., et al. IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach. Haematologica 2010, 96:472-476.
55. Linka R.M., et al. Loss-of-function mutations within the IL-2 inducible kinase ITK in patients with EBV-associated lymphoproliferative diseases. Leukemia 2012, 26:963-971.
56. Moshous D., et al. Whole-exome sequencing identifies Coronin-1A deficiency in 3 siblings with immunodeficiency and EBV-associated B-cell lymphoproliferation. J. Allergy Clin. Immunol. 2013, 131:1594-1603.
57. Abdollahpour H., et al. The phenotype of human STK4 deficiency. Blood 2012, 119:3450-3457.
58. Nehme N.T., et al. MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T-cell survival. Blood 2012, 119:3458-3468.
59. Gottschalk S., et al. Post-transplant lymphoproliferative disorders. Annu. Rev. Med. 2005, 56:29-44.
60. Angulo I., et al. Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage. Science 2013, 342:866-871.
61. Lucas C.L., et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. Nat. Immunol. 2014, 15:88-97.
62. van Montfrans J.M., et al. CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia. J. Allergy Clin. Immunol. 2012, 129:787-793.
63. Salzer E., et al. Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27. Haematologica 2012, 98:473-478.
64. Rowe M., et al. Distinctions between endemic and sporadic forms of Epstein-Barr virus-positive Burkitt's lymphoma. Int. J. Cancer 1985, 35:435-441.
65. Li F.Y., et al. Loss of MAGT1 abrogates the Mg2+ flux required for T cell signaling and leads to a novel human primary immunodeficiency. Magnes. Res. 2011, 24:S109-S114.
66. Li F.Y., et al. Second messenger role for Mg2+ revealed by human T-cell immunodeficiency. Nature 2011, 475:471-476.
67. Chaigne-Delalande B., et al. Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science 2013, 341:186-191.
68. Bar R.S., et al. Fatal infectious mononucleosis in a family. N. Engl. J. Med. 1974, 290:363-367.
69. Purtilo D.T., et al. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet 1975, 1:935-940.
70. Provisor A.J., et al. Acquired agammaglobulinemia after a life-threatening illness with clinical and laboratory features of infectious mononucleosis in three related male children. N. Engl. J. Med. 1975, 293:62-65.
71. Booth C., et al. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood 2011, 117:53-62.
72. Cannons J.L., et al. SLAM family receptors and SAP adaptors in immunity. Annu. Rev. Immunol. 2011, 29:665-705.
73. Rigaud S., et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 2006, 444:110-114.
74. Filipovich A.H., et al. X-linked lymphoproliferative syndromes: brothers or distant cousins?. Blood 2010, 116:3398-3408.
75. Pachlopnik Schmid J., et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood 2011, 117:1522-1529.
76. Rigaud S., et al. Human X-linked variable immunodeficiency caused by a hypomorphic mutation in XIAP in association with a rare polymorphism in CD40LG. Blood 2011, 118:252-261.
77. Parolini S., et al. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J. Exp. Med. 2000, 192:337-346.
78. Hislop A.D., et al. Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets. Blood 2010, 116:3249-3257.
79. Snow A.L., et al. Restimulation-induced apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease caused by SAP deficiency. J. Clin. Invest. 2009, 119:2976-2989.
80. Palendira U., et al. Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP. PLoS Biol. 2011, 9:e1001187.
81. Palendira U., et al. Expansion of somatically reverted memory CD8+ T cells in patients with X-linked lymphoproliferative disease caused by selective pressure from Epstein-Barr virus. J. Exp. Med. 2012, 209:913-924.
82. Orlova N., et al. Persistent infection drives the development of CD8+ T cells specific for late lytic infection antigens in lymphocryptovirus-infected macaques and Epstein-Barr virus-infected humans. J. Virol. 2011, 85:12821-12824.
83. Leskowitz R.M., et al. CD4+ and CD8+ T-cell responses to latent antigen EBNA-1 and lytic antigen BZLF-1 during persistent lymphocryptovirus infection of rhesus macaques. J. Virol. 2013, 87:8351-8362.
84. Moghaddam A., et al. An animal model for acute and persistent Epstein-Barr virus infection. Science 1997, 276:2030-2033.
85. Wang F. Nonhuman primate models for Epstein-Barr virus infection. Curr. Opin. Virol. 2013, 3:233-237.
86. Ohashi M., et al. An Epstein-Barr virus encoded inhibitor of colony stimulating factor-1 signaling is an important determinant for acute and persistent EBV infection. PLoS Pathog. 2012, 8:e1003095.
87. Leung C., et al. Infectious diseases in humanized mice. Eur. J. Immunol. 2013, 43:2246-2254.
88. Traggiai E., et al. Development of a human adaptive immune system in cord blood cell transplanted mice. Science 2004, 304:104-107.
89. Strowig T., et al. Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J. Exp. Med. 2009, 206:1423-1434.
90. Yajima M., et al. T cell mediated control of Epstein-Barr virus infection in humanized mice. J. Infect. Dis. 2009, 200:1611-1615.
91. Jaiswal S., et al. Enhanced humoral and HLA-A2-restricted dengue virus-specific T-cell responses in humanized BLT NSG mice. Immunology 2012, 136:334-343.
92. Shultz L.D., et al. Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:13022-13027.
93. Tanaka S., et al. Development of mature and functional human myeloid subsets in hematopoietic stem cell engrafted NOD/SCID/IL2rgammaKO mice. J. Immunol. 2012, 188:6145-6155.
94. Strowig T., et al. Human NK cells of mice with reconstituted human immune system components require preactivation to acquire functional competence. Blood 2010, 116:4158-4167.
95. Meixlsperger S., et al. CD141+ dendritic cells produce prominent amounts of IFN-alpha after dsRNA recognition and can be targeted via DEC-205 in humanized mice. Blood 2013, 121:5034-5044.
96. Chijioke O.O.C., et al. Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection. Cell Rep. 2013, 5:1489-1498.
97. Bjorkstrom N.K., et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 2010, 116:3853-3864.
98. Ascherio A., Munger K.L. Epstein-barr virus infection and multiple sclerosis: a review. J. Neuroimmune Pharmacol. 2010, 5:271-277.
99. Hjalgrim H., et al. HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:6400-6405.
100. Bollard C.M. Improving T-cell therapy for epstein-barr virus lymphoproliferative disorders. J. Clin. Oncol. 2013, 31:5-7.
101. Long H.M., et al. Immunotherapy for Epstein-Barr virus-associated malignancies. Drug News Perspect. 2010, 23:221-228.
102. Cohen J.I., et al. Epstein-Barr virus: an important vaccine target for cancer prevention. Sci. Transl. Med. 2011, 3:107fs107.
103. Epstein M.A., et al. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964, 1:702-703.